Home > Insider Trading > Bridgebio Oncology Therapeutics Inc. > Profile

Bridgebio Oncology Therapeutics Inc. (BBOT)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Sector: Healthcare

Insider Roster

Marc Cobo, Principal Accounting Officer, 2026-09-14
Idan Elmelech, Coo & Principal Financial Ofcr, 2026-07-06
Yong Ben, Chief Med & Dev Officer, 2026-07-06

Marc Cobo, Principal Accounting Officer, 2026-09-14
Idan Elmelech, Coo & Principal Financial Ofcr, 2026-07-06
Yong Ben, Chief Med & Dev Officer, 2026-07-06
Pedro Beltran, President and Ceo, 2026-07-06
Bihua Chen, Large Shareholder, Director, 2026-07-06
P. Praveen Tipirneni, 2026-06-18
Frank Mccormick, 2026-06-18
F Peter Lebowitz, 2026-06-18
J. Raymond Kelleher, 2026-06-18
Jake Bauer, 2026-06-18
Neil Kumar, 2026-06-18
Uneek Mehra, 2026-05-05
M. Eli Wallace, Chief Executive Officer, 2026-01-06
Bridgebio Pharma Llc, 2025-10-16
Bridgebio Pharma, Inc., 2025-10-16
Michelle Doig, 2025-08-18
Nebojsa Obradovic, Chief Legal Officer, 2025-08-11
Caleb Tripp, Chief Financial Officer, 2025-08-11
Iii A Albert Holman, Other, 2025-08-11
C. Mark Mckenna, Other, 2025-08-11
P. John Schmid, Other, 2025-08-11
Helix Holdings Ii Llc, Large Shareholder, Director, 2025-02-10

Show All Insiders (22)

Insider Trading: Purchases See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Chen Large Shareholder, Officer, Director	$10.00	903,600	$9,036,000.00	903,600	2024-02-13	Filing
Chen Large Shareholder, Officer, Director	$10.00	1,427,040	$14,270,400.00	1,427,040	2024-02-13	Filing
Chen Large Shareholder, Officer, Director	$10.00	69,360	$693,600.00	69,360	2024-02-13	Filing

News See All

BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook

On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing...

Keep Reading →

September 12th, 2026 - Hedge Funds News